Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
Analysts at StockNews.com began coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report issued on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的分析师开始报道以下股票 Otonomy(纳斯达克股票代码:OTIC — 获取评级) 在周五发布的研究报告中。该公司对这家生物制药公司的股票设定了 “持有” 评级。
Separately, Piper Sandler lowered shares of Otonomy from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $3.00 to $0.50 in a research note on Thursday, October 13th.
另外,派珀·桑德勒在10月13日星期四的一份研究报告中将Otonomy的股票从 “增持” 评级下调至 “中性” 评级,并将该股的目标价格从3.00美元下调至0.50美元。
Otonomy Price Performance
Otonomy 价格表现
Shares of NASDAQ OTIC opened at $0.11 on Friday. The firm has a market cap of $7.40 million, a PE ratio of -0.14 and a beta of 1.55. Otonomy has a 12-month low of $0.06 and a 12-month high of $2.59. The company's fifty day simple moving average is $0.10 and its 200 day simple moving average is $0.25.
纳斯达克OTIC的股票周五开盘价为0.11美元。该公司的市值为740万美元,市盈率为-0.14,beta值为1.55。Otonomy创下12个月低点0.06美元,12个月高点2.59美元。该公司的五十天简单移动平均线为0.10美元,其200天简单移动平均线为0.25美元。
Institutional Trading of Otonomy
自主学的机构交易
Several institutional investors and hedge funds have recently made changes to their positions in OTIC. Point72 Asset Management L.P. purchased a new stake in shares of Otonomy in the third quarter valued at about $1,621,000. Lynx1 Capital Management LP increased its holdings in Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after buying an additional 2,282,880 shares during the last quarter. Requisite Capital Management LLC purchased a new stake in Otonomy during the third quarter worth about $44,000. Dimensional Fund Advisors LP increased its holdings in Otonomy by 17.7% during the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock worth $2,020,000 after buying an additional 126,747 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in Otonomy by 129.2% during the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 80,153 shares during the last quarter. Hedge funds and other institutional investors own 41.23% of the company's stock.
一些机构投资者和对冲基金最近更改了他们在OTIC的头寸。Point72 Asset Management L.P. 在第三季度购买了Otonomy的新股份,价值约16.1万美元。Lynx1 Capital Management LP在第三季度将其在Otonomy的持股量增加了7,609.6%。Lynx1 Capital Management LP在上个季度又购买了2,282,880股股票后,现在拥有这家生物制药公司的2312,880股股票,价值68.2万美元。Requiend Capital Management LLC在第三季度购买了Otonomy的新股份,价值约44,000美元。Dimension Fund Advisors LP在第一季度将其在Otonomy的持股量增加了17.7%。Dimension Fund Advisors LP在上个季度又购买了126,747股股票后,现在拥有这家生物制药公司的841,694股股票,价值202万美元。最后,Two Sigma Investments LP在第三季度将其在Otonomy的持股量增加了129.2%。Two Sigma Investments LP在上个季度又购买了80,153股股票后,现在拥有这家生物制药公司142,183股股票,价值42,000美元。对冲基金和其他机构投资者拥有该公司41.23%的股票。
About Otonomy
关于自主学
(Get Rating)
(获取评分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc是一家生物制药公司。从事神经病学疗法的开发。该公司的产品线包括OTIVIDEX(地塞米松)梅尼尔病、OTIPRIO(环丙沙星视力悬浮液)急性带管中耳炎(AOMT)、OTO-313(加环素)耳鸣、OTO-413(BDNF)隐性听力损失、OTO-510(耳保护剂)预防CIHL、OTO-6XX(毛细胞再生)严重听力损失。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- The Uptrend in PepsiCo Stays Intact
- 3 Outperforming Stocks Partying Like It's 2020
- Disney Stock and The Bob Iger Effect
- Why Do Penny Stocks Often Crash After Rallies?
- This Is Why You Shouldn't Be So Happy About The Labor Data
- 免费获取 StockNews.com 关于自主学的研究报告(OTIC)的副本
- 百事可乐的上升趋势保持不变
- 3 只跑赢大盘的股票像 2020 年一样狂欢
- 迪士尼股票和鲍勃·艾格效应
- 为什么细价股经常在涨势后暴跌?
- 这就是为什么你不应该对劳工数据感到如此高兴
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。